Navigation Links
Genmab Announces Update on Recruitment of Patients in ofatumumab CLL Pivotal Study
Date:11/28/2007

Summary: Genmab and GlaxoSmithKline Have Completed Recruitment of 66 CLL Patients Respectively to Both Study Groups in a Pivotal Study of ofatumumab

COPENHAGEN, Denmark, November 28 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today recruitment of 132 patients has been completed in a pivotal study of ofatumumab (HuMax-CD20(R)) for the treatment of refractory chronic lymphocytic leukemia (CLL). This cohort comprises 66 patients who are refractory to both fludarabine and alemtuzumab and 66 fludarabine refractory patients who are considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. An interim analysis will be conducted on this cohort when 24 week efficacy data are available. The study will remain open for recruitment in order to collect additional safety and efficacy data.

Ofatumumab is an investigational, fully human, next generation monoclonal antibody that targets a unique epitope of the CD20 receptor on the surface of b-cells. This epitope is different to the other anti-CD20 antibodies currently available or in development. Ofatumumab is being developed under a co-development and commercialization agreement between Genmab and GlaxoSmithKline.

"We look forward to seeing the study results of the interim analysis from both patient groups. It is our hope, due to the high unmet need amongst these patients, that registration may be possible in each indication, depending on the data generated and ongoing discussions with the regulatory authorities. Recruitment will continue to the trial," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.

About the study

The study includes CLL patients who are refractory to both fludarabine and alemtuzumab and patients who are refractory to fludarabine who are considered inappropriate candidates for alemtuzumab due to bulky tumor in their lymph nodes. Each group will be analyzed separately and it is hoped that, registration of ofatum
'/>"/>

SOURCE Genmab A/S
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Genmab Announces 2007 First Half Year Results
2. Genmab Announces Encouraging Preclinical Data for ofatumumab
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Genmab Announces Asset Exchange Agreement
5. Genmab Amends Ofatumumab Pivotal Study in NHL to Single Arm Study
6. Genmab A/S - Company Announcement
7. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
8. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
9. Genmab Announces Results for the First Nine Months of 2007
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , DURHAM, N.C., Nov. 25 Rese...first energy-efficient, single-treatment water pur...n nanotubes to Andhra Pradesh, Minister of Rural W...ers in Hyderabad, India today. Initial tests, perf...ur, confirmed that the majority of the drinking wa...
(Date:11/25/2009)... , BEIJING, Nov. 25 /PRNewswire-Asia/ --...and provider of vaccines, announced today that it ...sh Sinovac (Dalian) Vaccine,Technology Co., Ltd. (...oduce,and commercialize human-use vaccines. Sinova...developing and commercializing world-class vaccine...
(Date:11/24/2009)... Ambassador to also Visit Detroit ...9 -- , , ,Who: David Appia, French Ambassador for ...the Invest in France Agency, , , , ,What: Ambassa...ss recent pro-business initiatives adopted by Fran...ademic landscape for innovation and development., ...
(Date:11/24/2009)..., ST. LOUIS, Nov. 24 ... presenting at the NASDAQ OMX conference on Tuesda...US/CST. Interested parties may listen via live aud...://inve s tor.sig m a a ldrich.com/ . User.... ,, About Sigma-Aldrich: Sigma-Aldrich i...
Breaking Biology Technology:North Carolina-based Cnanoz Unveils NanoPure(TM) to Government Leaders in Hyderabad, India 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 2Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities 3
...he following statement,was issued today by the law...Notice is hereby given that a class action lawsuit... the Southern District of Ohio on behalf of,all pu...: LCAV ) ("LCA" or,the "Company") from February 1...ss Period"). If you wish to discuss this action o...
... 1 AviaraDx announced today that,the company,s Ca... its,College of American Pathology (CAP) accredita...logy tests to hospitals and physicians across the,...ression assay capable of classifying,39 tumor type...ication of metastatic,cancer and guides the physic...
...s Johnson Space Center,has awarded a five-year, $1...with the National Space Biomedical Research Instit...tension, the institute and NASA,s Human,Research P...t of a,long-term human presence in space., The ba... 1, 1997, with,a value of $93.6 million. The first...
Other Biology Technology:Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3AviaraDx Announces CAP Accreditation of Its Laboratory Operations 2
(Date:11/26/2009)...erg, 27 November 2009 What are the bare essential...to produce a cell that can survive on its own? Can...understand how an entire organism functions as a s...cientists in a partnership between the European Mo...ermany, and the Centre de Regulacio Genmica (CRG) ...
(Date:11/25/2009)... Bacteria don,t have easy lives. In addition to m...y have natural enemies called bacteriophages, viru... days. , Still, bacteria and another class of m...extreme environments such as deep-sea volcanic ven...hey have a built-in defense system that helps prot...
(Date:11/25/2009)...urse of a lifetime, the heart pumps some 250 milli...to do this, the muscle fibers of the heart have to...y Dr. Wolfgang Rottbauer, vice chair of the Depart...ital (Chairman: Prof. Dr. H. A. Katus), has discov...ty of the smallest muscular unit, the sarcomere. I...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Researchers discover biological basis of 'bacterial immune system' 2Researchers discover biological basis of 'bacterial immune system' 3New genetic cause of cardiac failure discovered 21 in 6 health workers wont report in flu pandemic study by Ben Gurion U researchers 9397 11 in 6 health workers wont report in flu pandemic study by Ben Gurion U researchers 9397 21 in 6 health workers wont report in flu pandemic study by Ben Gurion U researchers 9397 3Corrective genes closer thanks to enzyme modification 9393 1Older Diabetics Should Avoid Dementia Meds 52962 1Older Diabetics Should Avoid Dementia Meds 52962 2
... of HIV-1 to develop high levels of genetic divers...es contributes to our difficulties in producing a ...ent algorithm to develop vaccines that cope with t... This computational method clarifies and analyzes ... describing the molecules which stimulate the immu...
... researchers report that freezing kidney tumors th...patients who are not good candidates for surgery. ...n more than 90 percent of selected patients are pu...standard treatment for kidney tumors is surgery, p...or some patients, surgery is not an option, and Ma...
...to a box glowing with fluorescent light, Stacie Gr...e says, holding the clear plastic up to her face. .... "It,s growing really well," she says, handing it...o his eye. "Yes," he says, with a boyish grin, "th...ngus success story means nothing is growing at the...
Other Biology News:Cryoablation -- A new treatment option for some kidney tumor patients 2Cryoablation -- A new treatment option for some kidney tumor patients 3Immunization rates hit record high in poor countries 2Immunization rates hit record high in poor countries 3
Multiskan EX from Thermo Scientific
...ti-tasking vacuum source and solvent recovery syst...and a maintenance-free, oil-free vacuum pump in a ...h glass condensation flask collects all the recove... UVS400 provides an ideal vacuum system for use wi...
Mouse Anti-Ubiquitin, Multi Monoclonal Antibody, Unconjugated, Clone FK2 from Assay Designs/Stressgen Bioreagents
Goat Anti-Lysozyme C (W-20) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: